RemeGen Co., Ltd. has called its 2025 annual general meeting (AGM) for 16 June 2026 in Yantai to vote on 13 resolutions spanning financial results, capital management, board renewal and project funding re-allocation.
Financial performance • 2025 revenue rose 89.36% year on year to RMB 3.25 billion, fuelled by RMB 2.31 billion in product sales of telitacicept and disitamab vedotin and a jump in technology-licensing income. • Operating profit reached RMB 722.61 million versus a RMB 1.46 billion loss in 2024; net profit attributable to shareholders turned positive at RMB 709.65 million (2024: –RMB 1.47 billion). • The Board proposes no dividend or capitalisation of reserves for 2025.
Auditor re-appointment Ernst & Young Hua Ming LLP (PRC) and Ernst & Young (international) are nominated to audit the 2026 financial statements, with estimated fees of RMB 1.05 million and RMB 2.50 million respectively.
Director remuneration Total 2025 remuneration and share-based charges for executive directors: – Wang Weidong: RMB 7.75 million (incl. 5.61 million in share-based expense) – Fang Jianmin: RMB 5.44 million – Lin Jian: RMB 0.81 million – Wen Qingkai: RMB 3.41 million
Independent directors each received RMB 0.30 million. No remuneration was paid to the two non-executive directors. For 2026, internal directors will continue to receive role-based salary and incentives; external and independent directors will be paid fixed allowances.
Board reshuffle Shareholders will elect a new three-year board term: • Executive director nominees – Wang Weidong, Fang Jianmin, Wen Qingkai and newcomer Fang Michelle Yi. • Non-executive director nominee – Wang Liqiang (re-election). • Independent non-executive director nominees – incumbent Chen Yunjin and Huang Guobin, plus new candidate Song Xiliang. Elections will use cumulative voting.
Capital measures • The Board seeks a 12-month general mandate to issue up to 20% of the Company’s issued share capital, excluding treasury shares (maximum 112.86 million shares based on the current 564.28 million issued shares minus treasury stock). • Registered capital will rise to RMB 564.48 million following attribution of restricted A-shares; corresponding amendments to the Articles of Association are proposed.
Use of A-share IPO proceeds RemeGen will discontinue three clinical sub-projects – RC88, RC108 and RC118 – and reallocate their combined unused proceeds of RMB 103.49 million to advance RC148, a bispecific antibody targeting PD-1/VEGF currently entering Phase III trials for NSCLC and Phase II/III for colorectal cancer. Total planned investment for all IPO-funded projects remains unchanged.
Governance updates Shareholders will vote on revised Board procedural rules and a new Remuneration Management Policy for directors and senior management.
Meeting logistics H-shareholders on record as of 11 June 2026 may attend or vote by proxy at the AGM on 16 June 2026 in Yantai.
Comments